A phase 1/2 study to evaluate the combination of TG4001 with Avelumab in patients with HPV-Positive head & neck cancers

Trial Profile

A phase 1/2 study to evaluate the combination of TG4001 with Avelumab in patients with HPV-Positive head & neck cancers

Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Avelumab (Primary) ; Tipapkinogene sovacivec (Primary)
  • Indications Head and neck cancer; Oropharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2017 According to a Transgene media release, first patient enrollment expected in 2H 2017. Prof. Christophe Le Tourneau will be principal investigator of this study.
    • 26 Oct 2016 New trial record
    • 20 Oct 2016 According to a Transgene media release, this study is expected to start in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top